Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

Investigating Pseudomonas Susceptibility to Ceftolozane/tazobactam

JUL 22, 2017 | CONTAGION® EDITORIAL STAFF


Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains his team’s study regarding the susceptibility of Pseudomonas isolates to ceftolozane/tazobactam.

Interview Transcript (slightly modified for readability)

“Our study was simple; it was kind of a big data-type study where we just looked at 80 different hospitals, and basically any time that any of those hospitals on a given isolate, tested one of their Pseudomonas isolates to ceftolozane/tazobactam, we looked at the in vitro susceptibilities; we wanted to see if it was active or not.

I think it’s important to keep in mind when you look at those data that there’s going to be a selection bias that comes with that, because we only test this drug, when we can’t use the other one; so, they’re going to be more resistant pathogens in general. But what we found was that even though the vast majority of those were resistant to other traditional beta-lactam therapies, over 80% of them were still susceptible to ceftolozane, and that actually included about 80% susceptibility against nearly 200 Pseudomonas isolates that were resistant to all of the other beta-lactam options. Once again, making the case that it is really an unmet need or a niche from that standpoint.”

DISCLOSURES: Jason Pogue is a Consultant for Merck, Allergan, Med Co, Shionogi, Zavante, Achaogen. This study was supported by a grant from Merck.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


Advocacy and Research Foundation Partners
FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.